ライフサイエンスコーパス: 3,4-dihydroxyphenylalanine

1 or aryloxy radical coupling to form di-DOPA (3,4-dihydroxyphenylalanine).

2 -stimulating hormone, 8-methoxypsoralen, and 3,4-dihydroxyphenylalanine).

3 nt motor deficits that can be rescued with L-3,4 dihydroxyphenylalanine.

4 inst tyrosine and to a lesser extent against 3,4-dihydroxyphenylalanine.

5 d were not related to melanin formation from 3,4-dihydroxyphenylalanine.

6 stinctly unusual ones, 6-bromotryptophan and 3,4-dihydroxyphenylalanine.

7 6-(18)F-fluoro-l-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET is a useful

8 ibution, and prognostic value of fused (18)F-3,4-dihydroxyphenylalanine ((18)F-DOPA) PET/MR images in

9 ination of protein-bound 3-nitrotyrosine and 3, 4-dihydroxyphenylalanine (3-hydroxytyrosine) as speci

10 It was able to block the L-3,4-dihydroxyphenylalanine accumulation produced by CI-1

11 mino)methyl]chromen-2-one, increased DOPA (L-3,4-dihydroxyphenylalanine) accumulation 51% in the hipp

12 The incorporation of the amino acid DOPA (3,4-dihydroxyphenylalanine) allows the self-assembled na

13 demonstrated by rescue of the dysfunction by 3, 4-dihydroxyphenylalanine and considerable dopaminergi

14 L-3,4-dihydroxyphenylalanine and reserpine have been used

15 icroscopy have been used to determine that l-3,4-dihydroxyphenylalanine and reserpine increase and de

16 rs (alpha-melanocyte-stimulating hormone and 3,4-dihydroxyphenylalanine) and inhibitors (hydroquinone

17 abundance and proximity of catecholic Dopa (3,4-dihydroxyphenylalanine) and lysine residues hint at

18 e precursor and Parkinson's therapy agent, L-3,4-dihydroxyphenylalanine, and at cell clusters incubat

19 Dopamine (DA), its precursor 3,4-dihydroxyphenylalanine, and metabolite 3,4-dihydroxy

20 as: Trp > norleucine > Phe, Leu > Ile > His >3,4-dihydroxyphenylalanine, Arg > Val > Lys, Tyr, Pro >

21 reatment with a norepinephrine precursors (l-3,4-dihydroxyphenylalanine at 100 mg/kg or l-threo-dihyd

22 ich catalyzes the oxidation of serotonin and 3,4-dihydroxyphenylalanine by H(2)O(2).

23 anogenic enzymes include Tyrp1 (or TRP1) and 3,4-dihydroxyphenylalanine-chrome tautomerase (Dct or TR

24 Aspartate 1-decarboxylase (ADC) and 3,4-dihydroxyphenylalanine decarboxylase (DDC) provide b

25 des a new member of the opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylase gene family (Ty

26 ive identity with other opium poppy tyrosine/3,4-dihydroxyphenylalanine decarboxylases (84%), and whe

27 3, 4-Dihydroxyphenylalanine (Dopa) residues in Mfps medi

28 The high content of 3,4-dihydroxyphenylalanine (Dopa) (~30 mol %) and its lo

29 g), a 5-HT(1A) receptor agonist, decreased l-3,4-dihydroxyphenylalanine (DOPA) accumulation in rat st

30 developed for enantiomeric quantification of 3,4-dihydroxyphenylalanine (DOPA) and its precursors, ph

31 ter cuticle of byssal threads given its high 3,4-dihydroxyphenylalanine (Dopa) content at 10-15 mol %

32 Concomitantly, GBL treatment [along with the 3,4-dihydroxyphenylalanine (dopa) decarboxylase inhibito

33 easuring dopamine synthesis (accumulation of 3,4-dihydroxyphenylalanine (DOPA) following decarboxylas

34 p(1) residue of alpha-factor was replaced by 3,4-dihydroxyphenylalanine (DOPA) for periodate-mediated

35 xylbetaine) (pCB) and four surface-binding l-3,4-dihydroxyphenylalanine (DOPA) groups, pCB-(DOPA)4, w

36 The interaction between a 3,4-dihydroxyphenylalanine (DOPA) labeled analogue of th

37 in chemically defined minimal medium with L-3,4-dihydroxyphenylalanine (DOPA) or (-)-epinephrine pro

38 lated nonenzymatically to the DA precursor l-3,4-dihydroxyphenylalanine (DOPA) under pro-oxidant cond

39 mic the cross-linking of proteins containing 3,4-dihydroxyphenylalanine (DOPA) used by shellfish for

40 aining sequences in polypeptides to peptidyl 3,4-dihydroxyphenylalanine (DOPA) using mushroom tyrosin

41 egy exploits the adhesive characteristics of 3,4-dihydroxyphenylalanine (DOPA), an important componen

42 inactive against tyrosine, phenylalanine and 3,4-dihydroxyphenylalanine (dopa), tdc1 was developmenta

43 (A. pectinata foot protein-1, apfp-1) with L-3,4-dihydroxyphenylalanine (DOPA)-containing and mannose

44 As the first of the 3,4-dihydroxyphenylalanine (Dopa)-containing byssal prec

45 We found that only l-3,4-dihydroxyphenylalanine (DOPA)-containing peptides we

46 We previously reported l-3,4-dihydroxyphenylalanine (dopa)-histidine (dopa-His) a

47 ilable animal models of PD fail to display l-3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonis

48 is expressed by the selective recognition of 3,4-dihydroxyphenylalanine (DOPA).

49 ine, trans-2,3-cis-3,4-dihydroxyproline, and 3,4-dihydroxyphenylalanine (Dopa).

50 ulfotransferase (PST), SULT1A3, has a unique 3,4-dihydroxyphenylalanine (Dopa)/tyrosine-sulfating act

51 levels of dopamine (DA) and its metabolites, 3,4-dihydroxyphenylalanine (DOPAC) and homovanillic acid

52 ic amines significant to the fly including L-3,4-dihydroxyphenylalanine, dopamine, tyramine, and sero

53 ehaviorally effective dose of DA precursor l-3,4-dihydroxyphenylalanine effectively reversed these ch

54 ically relevant cargos, nipecotic acid and l-3,4-dihydroxyphenylalanine (i.e., l-DOPA), were attached

55 alyzes the hydroxylation of tyrosine to form 3,4-dihydroxyphenylalanine in the biosynthesis of the ca

56 Dopa (3,4-dihydroxyphenylalanine) is recognized as a key chemi

57 represents decarboxy-(E)-alpha,beta-dehydro-3,4-dihydroxyphenylalanine, is a potently antimicrobial

58 ptophan, R(**) is dihydroxyarginine, Y(*) is 3,4-dihydroxyphenylalanine, K(*) is 5-hydroxylysine, and

59 dopamine receptor agonists apomorphine and L-3, 4-dihydroxyphenylalanine (L-DOPA).

60 tivity in dopamine-deficient mice than did l-3,4-dihydroxyphenylalanine (l-dopa) administration, whic

61 escribe a simple one-pot method, employing l-3,4-dihydroxyphenylalanine (L-DOPA) as a reducing/cappin

62 Treatment of Parkinson disease (PD) with L-3,4-dihydroxyphenylalanine (L-DOPA) dramatically relieve

63 DA-/-) mice required daily administration of 3,4-dihydroxyphenylalanine (L-DOPA) for survival beyond

64 The application of L-3,4-dihydroxyphenylalanine (L-DOPA) increased the IPSC i

65 The dopamine precursor L-beta-3,4-dihydroxyphenylalanine (L-DOPA) inhibited cleavage o

66 th saline; a synthetic dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA) methyl ester; a dire

67 nist SKF 82958 and the indirect DA agonist L-3,4-dihydroxyphenylalanine (L-DOPA) on the acoustic star

68 was tested in 7 aged rhesus monkeys using L-3,4-dihydroxyphenylalanine (L-dopa) or the selective dop

69 Although L-3,4-dihydroxyphenylalanine (L-DOPA) remains the referenc

70 he loss of midbrain dopaminergic neurons and 3,4-dihydroxyphenylalanine (L-DOPA) reversible behaviora

71 ent of dyskinesia that result from chronic L-3,4-dihydroxyphenylalanine (L-DOPA) therapy.

72 Daily treatment of DD mice with L-3,4-dihydroxyphenylalanine (L-DOPA) transiently restores

73 to dopamine D1 or D2 receptor agonists and l-3,4-dihydroxyphenylalanine (l-DOPA) was 3- to 13-fold gr

74 aring" clinical practice that avoids using L-3,4-dihydroxyphenylalanine (L-DOPA), a dopamine precurso

75 can be achieved by daily administration of L-3,4-dihydroxyphenylalanine (L-dopa), a precursor of dopa

76 y treated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (L-DOPA), but its prolonged u

77 anging freely, and injected with 100 mg/kg l-3,4-dihydroxyphenylalanine (L-DOPA), engage in a behavio

78 dministration of the antiparkinsonian drug l-3,4-dihydroxyphenylalanine (l-DOPA), is accompanied by a

79 ve significantly less amounts of dopamine, l-3,4-dihydroxyphenylalanine (L-DOPA), salsolinol, and N-a

80 is disrupted in Parkinson's disease and in l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesia (

81 BST) as a structure putatively involved in L-3,4-dihydroxyphenylalanine (L-Dopa)-induced dyskinesia (

82 antagonists have targeted PD patients with L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

83 developed treatment complications known as L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

84 rch of brain nuclei putatively involved in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

85 Furthermore, in a mouse model of L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (

86 L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia i

87 ly the 3-hydroxylation of tyrosine to form l-3,4-dihydroxyphenylalanine (l-DOPA).

88 can be maintained by daily treatment with l-3,4-dihydroxyphenylalanine (L-dopa).

89 can be synthesized by another pathway via l-3,4-dihydroxyphenylalanine (L-DOPA).

90 on unless the animals were pretreated with l-3,4-dihydroxyphenylalanine (l-dopa).

91 administration of the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-dopa).

92 lls incubated with the dopamine precursor, L-3,4-dihydroxyphenylalanine (L-DOPA).

93 They are rescued by daily treatment with L-3,4-dihydroxyphenylalanine (L-DOPA); each dose restores

94 pamine is restored by daily treatment with l-3-4-dihydroxyphenylalanine (l-dopa).

95 l-3,4-dihydroxyphenylalanine-mediated dyskinesias were als

96 Dopamine- and 3,4-dihydroxyphenylalanine-melanin products were identif

97 Ultraviolet-Vis absorbance spectra of L-3,4-dihydroxyphenylalanine-melanin solutions at differen

98 Analytes including L-3,4-dihydroxyphenylalanine, N-acetyl octopamine, N-acety

99 slation remains largely limited to the Dopa (3,4-dihydroxyphenylalanine) or catechol functionality, w

100 aling using the dopamine precursor l-DOPA (l-3,4-dihydroxyphenylalanine) or dopamine receptor agonist

101 In cultured human RPE, KL increases the l-3,4-dihydroxyphenylalanine synthesis and inhibits vascul

102 omeno[3,4-c]pyridin-5-one, increased DOPA (L-3,4-dihydroxyphenylalanine) synthesis 84% in the hippoca

103 L-3,4-dihydroxyphenylalanine, the immediate precursor of d

104 tor behaviors (dyskinesias) in response to l-3,4-dihydroxyphenylalanine, the principal treatment for

105 nephrine, norepinephrine, octopamine (OA), L-3, 4-dihydroxyphenylalanine, tyramine (TA), and serotoni